Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prolymphocytic leukemia.

Ahmed Absi1, Eric Hsi, Matt Kalaycio

  • 1Taussig Cancer Cancer, The Cleveland Clinic Foundation, 9500 Euclid Avenue R35, Cleveland OH 44195, USA.

Current Treatment Options in Oncology
|May 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel.

Frontiers in medicine·2026
Same author

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.

Blood advances·2025
Same author

Myeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms.

Hematology/oncology and stem cell therapy·2025
Same author

Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil.

Bone marrow transplantation·2025
Same author

Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients.

Pharmacy (Basel, Switzerland)·2025
Same author

Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system.

Expert review of clinical pharmacology·2025

T-cell prolymphocytic leukemia is aggressive, but alemtuzumab offers better remission rates than pentostatin. Stem cell transplant is recommended for select patients. B-cell prolymphocytic leukemia may respond to fludarabine, with rituximab showing promise.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Prolymphocytic leukemia (PLL) is a rare chronic lymphoproliferative disorder with distinct B-cell and T-cell subtypes.
  • T-cell PLL (T-PLL) is characterized by an aggressive clinical course, short survival, and poor response to conventional chemotherapy.

Purpose of the Study:

  • To review current treatment strategies for T-cell and B-cell prolymphocytic leukemia.
  • To evaluate the efficacy of purine analogues, alemtuzumab, and stem cell transplantation in T-PLL.
  • To discuss management options for B-PLL, including fludarabine, splenic interventions, and rituximab.

Main Methods:

  • Review of existing literature on T-cell and B-cell prolymphocytic leukemia treatments.
  • Analysis of treatment outcomes with pentostatin, alemtuzumab, and stem cell transplantation (SCT) in T-PLL.

Related Experiment Videos

  • Assessment of fludarabine, splenic irradiation, splenectomy, and rituximab in B-PLL management.

    • Main Results:

    • Pentostatin yields major responses in over half of T-PLL patients, with a minority achieving complete remission.
    • Alemtuzumab demonstrates higher complete remission rates than pentostatin, especially in patients progressing on pentostatin.
    • Stem cell transplant (SCT) is a viable option for select young, healthy T-PLL responders.
    • Fludarabine can achieve prolonged progression-free survival in some B-PLL patients.
    • Splenic irradiation or splenectomy effectively palliates massive splenomegaly in B-PLL.

    Conclusions:

    • Alemtuzumab is recommended as initial therapy for T-PLL, followed by SCT for eligible responders.
    • Fludarabine offers prolonged progression-free survival for some B-PLL patients.
    • Rituximab shows promise for B-PLL, warranting further investigation.